
Chinese pharmaceutical group listed on the Shenzhen Stock Exchange under code 002653, founded on 26 August 2005 as Tibet Kangxin Pharmaceutical, renamed Tibet Haisco Pharmaceutical Group in 2010, converted into a joint stock company that August with 190 million yuan of registered capital and renamed Haisco Pharmaceutical Group in March 2016, with its main operations at Sichuan Haisco Pharmaceutical in Chengdu. Manufactures, wholesales, imports and exports medicines, and has moved from generics and parenteral nutrition into innovative small molecule drugs in anaesthesia and analgesia, metabolic disease and oncology, most notably the anaesthetic ciprofol.
View Company Profile
Leave your rating